Literature DB >> 3650111

HIV-specific antibody among voluntary blood donors in Lower Saxony (FRG).

G Caspari, J Beyer, F Schunter, J Knüver-Hopf, H Schmitt.   

Abstract

Anti-HIV test results of the Red Cross Blood Transfusion Service of Lower Saxony from 1 June 1985 to 31 July 1986 inclusive were analysed retrospectively. Nine out of 70,936 donors who had not donated blood before 1 June 1985 (first-time donors) and 9 out of 261,231 donors who had donated blood before this date (repeating donors) were found anti-HIV confirmed positive at the time of the first blood donation during the study period. The prevalence of HIV antibody in first-time donors was significantly higher than in repeating donors (p less than 0.01). It was concluded that some members of risk groups used blood donation to obtain an anti-HIV test result. One out of 30,300 blood donations was confirmed anti-HIV positive. The results of this study justify the transfusion of blood donations that are reactive only in the initial ELISA test.

Mesh:

Substances:

Year:  1987        PMID: 3650111     DOI: 10.1007/BF00320575

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  10 in total

1.  Military statistics on AIDS in the u.s.

Authors:  D M Barnes
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

2.  Provisional Public Health Service inter-agency recommendations for screening donated blood and plasma for antibody to the virus causing acquired immunodeficiency syndrome.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1985-01-11       Impact factor: 17.586

3.  Seroepidemiology of HTLV-III (LAV) in the Federal Republic of Germany.

Authors:  G Hunsmann; J Schneider; H Bayer; R Kurth; A Werner; H D Brede; V Erfle; W Mellert; H R Brodt; L Bergmann
Journal:  Klin Wochenschr       Date:  1985-03-01

4.  [LAV/HTLV-III antibodies in blood and blood products].

Authors:  L Gürtler; J Eberle; F Deinhardt
Journal:  Dtsch Med Wochenschr       Date:  1985-10-25       Impact factor: 0.628

5.  [Incidence of HTLV-III antibodies in blood donors at the German Red Cross].

Authors:  B Kubanek; K Koerner
Journal:  Dtsch Med Wochenschr       Date:  1986-03-28       Impact factor: 0.628

6.  Prevalence of HTLV-III antibody in American blood donors.

Authors:  J B Schorr; A Berkowitz; P D Cumming; A J Katz; S G Sandler
Journal:  N Engl J Med       Date:  1985-08-08       Impact factor: 91.245

Review 7.  Transmission of human immunodeficiency virus (HIV/HTLV-III/LAV): a review.

Authors:  M van der Graaf; R J Diepersloot
Journal:  Infection       Date:  1986 Sep-Oct       Impact factor: 3.553

8.  AIDS: a challenge for the public health.

Authors:  E D Acheson
Journal:  Lancet       Date:  1986-03-22       Impact factor: 79.321

9.  Prevention of acquired immune deficiency syndrome (AIDS): report of inter-agency recommendations.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1983-03-04       Impact factor: 17.586

10.  Anti-HTLV-III screening of blood donors.

Authors:  P Kühnl; S Seidl; G Holzberger
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144

  10 in total
  3 in total

1.  HIV-2 antibody testing of blood donors with doubtful immunoblot results for HIV-1.

Authors:  J Knüver-Hopf; H Mohr; J Beyer; B Lambrecht; D Mix; H Rübsamen-Waigmann; H Schmitt
Journal:  Blut       Date:  1989-03

2.  Untargeted metabolomics and transcriptomics identified glutathione metabolism disturbance and PCS and TMAO as potential biomarkers for ER stress in lung.

Authors:  Zijing Wang; Peng Ma; Yisa Wang; Biyu Hou; Can Zhou; He Tian; Bowen Li; Guanghou Shui; Xiuying Yang; Guifen Qiang; Chengqian Yin; Guanhua Du
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

Review 3.  Insulin Resistance in HIV-Patients: Causes and Consequences.

Authors:  Marcelo N Pedro; Guilherme Z Rocha; Dioze Guadagnini; Andrey Santos; Daniela O Magro; Heloisa B Assalin; Alexandre G Oliveira; Rogerio de Jesus Pedro; Mario J A Saad
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-05       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.